Pharma dose CMOs face growth slowdown, but opportunities lie ahead
GlobalData’s expert trend report reveals that the slowdown marks a sharp contrast to the rapid growth seen in 2020-22
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Catalent
Pharma CMO M&A activity shifts focus to scaling in 2023: GlobalData
High inflation and interest rates along with an uncertain business environment have disincentivised investment. The focus shifts…
Catalent to help Novo Nordisk address production demands for Ozempic and Wegovy: GlobalData
The acquisition of Catalent by Novo Holdings expects to see three new manufacturing sites added to Novo Nordisk’s arsenal, to…
M&A activity of pharma CMOs will continue despite challenging borrowing environment: GlobalData
CMOs showed an increasing reluctance to take on debt in 2022. Even still, large CMOs made acquisitions of companies and facilities…
Moderna and Catalent announce collaboration for COVID-19 vaccine candidate
Catalent to provide vial filling and packaging capacity, as well as additional staffing to support the production of an initial…